[go: up one dir, main page]

MA31201B1 - Compositions pharmaceutiques comprenant un agent calcilytique - Google Patents

Compositions pharmaceutiques comprenant un agent calcilytique

Info

Publication number
MA31201B1
MA31201B1 MA32187A MA32187A MA31201B1 MA 31201 B1 MA31201 B1 MA 31201B1 MA 32187 A MA32187 A MA 32187A MA 32187 A MA32187 A MA 32187A MA 31201 B1 MA31201 B1 MA 31201B1
Authority
MA
Morocco
Prior art keywords
agent
calcitic
pharmacological compositions
short
rapid
Prior art date
Application number
MA32187A
Other languages
Arabic (ar)
English (en)
Inventor
Thomas Buhl
Elisabete Goncalves
Oscar Kalb
Lorenz Meinel
Sibylle Reidemeister
Agnes Taillardat
Leo Widler
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38016483&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31201(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA31201B1 publication Critical patent/MA31201B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'INVENTION CONCERNE UNE COMPOSITION PHARMACEUTIQUE COMPRENANT UN AGENT CALCILYTIQUE LEQUEL, LORSQU'ADMINISTRÉ PAR VOIE ORALE À UN SUJET, INDUIT UNE ABSORPTION RAPIDE ET DE COURTE DURÉE DE L'AGENT CALCILYTIQUE ET/OU UNE LIBÉRATION RAPIDE ET DE COURTE DURÉE DE L'HORMONE PARATHYROÏDIENNE
MA32187A 2007-03-02 2009-08-31 Compositions pharmaceutiques comprenant un agent calcilytique MA31201B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07103365A EP1964548A1 (fr) 2007-03-02 2007-03-02 Compositions pharmaceutiques comprenant un agent calcilytique

Publications (1)

Publication Number Publication Date
MA31201B1 true MA31201B1 (fr) 2010-02-01

Family

ID=38016483

Family Applications (1)

Application Number Title Priority Date Filing Date
MA32187A MA31201B1 (fr) 2007-03-02 2009-08-31 Compositions pharmaceutiques comprenant un agent calcilytique

Country Status (20)

Country Link
US (1) US20100022565A1 (fr)
EP (2) EP1964548A1 (fr)
JP (1) JP2010520179A (fr)
KR (1) KR20090125245A (fr)
CN (1) CN101621993A (fr)
AR (1) AR065564A1 (fr)
AU (1) AU2008223876A1 (fr)
CA (1) CA2678794A1 (fr)
CL (1) CL2008000617A1 (fr)
CO (1) CO6210808A2 (fr)
EC (1) ECSP099611A (fr)
GT (1) GT200900235A (fr)
IL (1) IL200274A0 (fr)
MA (1) MA31201B1 (fr)
MX (1) MX2009009343A (fr)
PE (1) PE20081794A1 (fr)
TN (1) TN2009000358A1 (fr)
TW (1) TW200843762A (fr)
WO (1) WO2008107390A1 (fr)
ZA (1) ZA200905472B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0606426D0 (en) * 2006-03-30 2006-05-10 Novartis Ag Benzimidazole derivatives
AU2007303846B2 (en) 2006-10-04 2011-03-10 Pfizer Products Inc. Pyrido[4,3-d]pyrimidin-4(3H)-one derivatives as calcium receptor antagonists
CA2913731C (fr) 2013-06-04 2021-05-25 Monosol Llc Solutions d'etancheification de films solubles dans l'eau, procedes associes et articles associes
CA3064371A1 (fr) * 2016-05-20 2017-11-23 Azure Biotech, Inc. Systemes destines a une administration vaginale comportant un modulateur selectif des recepteurs aux oestrogenes (serm) et leurs utilisations
JP6994061B2 (ja) 2019-02-15 2022-01-14 ノバルティス アーゲー ４－（７－ヒドロキシ－２－イソプロピル－４－オキソ－４ｈ－キナゾリン－３－イル）－ベンゾニトリルの製剤
KR102220255B1 (ko) * 2019-08-13 2021-02-26 동국대학교 산학협력단 수술 후 부갑상선기능저하증 개선 또는 치료용 약학 조성물 및 이를 이용한 치료 방법
WO2021029517A1 (fr) * 2019-08-13 2021-02-18 Dongguk University Industry-Academic Cooperation Foundation Composition pharmaceutique destinée à améliorer ou traiter l'hypoparathyroïdie post-chirurgicale et méthode de traitement l'utilisant
MX2023001438A (es) * 2020-08-04 2023-06-15 Calcilytix Therapeutics Inc Formulaciones de compuestos calciliticos de trifenilo.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202261B2 (en) * 1996-12-03 2007-04-10 Nps Pharmaceuticals, Inc. Calcilytic compounds
PE20001456A1 (es) * 1999-02-02 2001-01-28 Smithkline Beecham Corp Compuestos calcioliticos
US20060052345A1 (en) * 2002-11-04 2006-03-09 Nps Pharmaceuticals, Inc. Quinazolinone compounds as calcilytics

Also Published As

Publication number Publication date
ZA200905472B (en) 2010-04-28
TN2009000358A1 (en) 2010-12-31
IL200274A0 (en) 2010-04-29
WO2008107390A1 (fr) 2008-09-12
ECSP099611A (es) 2009-10-30
PE20081794A1 (es) 2009-01-09
GT200900235A (es) 2010-03-15
AU2008223876A1 (en) 2008-09-12
US20100022565A1 (en) 2010-01-28
MX2009009343A (es) 2009-09-11
CN101621993A (zh) 2010-01-06
KR20090125245A (ko) 2009-12-04
CA2678794A1 (fr) 2008-09-12
CO6210808A2 (es) 2010-10-20
AR065564A1 (es) 2009-06-17
JP2010520179A (ja) 2010-06-10
TW200843762A (en) 2008-11-16
EP1964548A1 (fr) 2008-09-03
EP2124893A1 (fr) 2009-12-02
CL2008000617A1 (es) 2008-09-12

Similar Documents

Publication Publication Date Title
MA31201B1 (fr) Compositions pharmaceutiques comprenant un agent calcilytique
CL2007002594A1 (es) Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
CL2006003672A1 (es) Compuestos derivados de pirimido-[4,5-b]-oxazinas; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de diabetes mellitus y/u obesidad.
MXPA05007328A (es) Composiciones que contienen agentes antiacne y el uso de las mismas.
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
CL2004001069A1 (es) Compuestos derivados de 1-benzoil-isoquinolinas sustituidos; procedimiento de preparacion, composicion farmaceutica; y uso para el tratamiento o profilaxis de diabetes tipo ii.
BR112015023391A8 (pt) formulações de conjugados anticorpo-droga anti-egfr
MA29675B1 (fr) Nouvelle formulation pharmaceutique contenant un biguanide et un derive de thiazolidinedione
BRPI0703142A (pt) sistema geométrico efetor de extremidade
CL2008000691A1 (es) Compuestos derivados de dihidro y tetrahidro oxazolopirimidinonas sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento de la esquizofrenia, epilepsia, entre otras enfermedades.
BRPI0922435A2 (pt) "composto de tiazolopiridina moduladores de sirtuina, composição farmacêutica compreendendo o mesmo e seu uso."
CL2007001049A1 (es) Uso de un compuesto que altera al receptor de interleuquina 1 (il-1) para el tratamiento de enfermedades o trastornos oftalmicos; y composicion farmaceutica que comprende el compuesto il-1.
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
EP2093237A4 (fr) Agent anticancéreux comprenant un anticorps anti-hb-egf en tant qu'ingrédient actif
MA41138B1 (fr) Formulation à rapport fixe d'insuline glargine/lixisenatide
BRPI0814891A2 (pt) Composição farmacêutica contendo composto oticamente ativo tendo atividade agonista de receptor de trombopoietina, e intermediário do mesmo.
CL2007003643A1 (es) Composicion farmaceutica de azimilidina que comprende 0,5% a aproximadamente 2,5% (w/w) de agua; y uso para el tratamiento de arritmias cardiacas.
WO2007064773A3 (fr) Composes de benzothiazole marques aux isotopes utiles en tant qu'agents d'imagerie pour des proteines amyloidogeniques
WO2007013666A3 (fr) Agents anti-tumeur comprenant des r-spondines
MA31430B1 (fr) Formulation a liberation prolongee de nevirapine
CL2007002769A1 (es) Compuestos derivados de sulfonamida; procedimiento de obtencion; composicion farmaceutica; y uso en el tratamiento de la diabetes.
WO2007143382A3 (fr) Formulations de loratadine liquide pour voie orale et procédés
BR0314241B1 (pt) composto, processos para a preparaÇço do mesmo e para a carbonilaÇço de um composto etilenicamente insaturado, composiÇço, e, uso de um composto ou de uma composiÇço.
CL2007003847A1 (es) Compuestos derivados de pirimidinas 2,4,5 tri-sustituidas; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento del cancer.
TW200621160A (en) Anti-termite agent